[Federal Register: January 30, 2007 (Volume 72, Number 19)]
[Notices]
[Page 4284-4285]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr30ja07-94]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Co-Exclusive License: Prevention and
Treatment of Human Cancer and Tumors by Inhibitors of Any or All of the
Adenosine Receptor Subtypes Covered by the Licensed Patent Rights
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH),
Department of Health and Human Services, is contemplating the grant of
a co-exclusive license to practice the invention embodied in Patent
Applications U.S. 60/340,772, filed on 12/12/2001, U.S. 60/342,582,
filed on 12/19/2001, PCT/US2002/036829, filed on 11/14/2002, and
corresponding EP, CA, AU, and JP filings, as well as U.S. 10/498,416,
filed on 06/10/2004; entitled ``Methods for using extracellular
adenosine inhibitors and adenosine receptor inhibitors to enhance
immune response and inflammation'', all by Michail V. Sitkovsky, and
Akio Ohta, to Redox Therapies, Inc., having a place of business in
Boston, MA. The patent rights in this invention have been assigned to
the United States of America.
DATES: Only written comments and/or application for a license that are
received by the NIH Office of Technology Transfer on or before April 2,
2007 will be considered.
ADDRESSES: Requests for a copy of the patent application, inquiries,
comments and other materials relating to the contemplated license
should be directed to: Cristina Thalhammer-Reyero, Ph.D., M.B.A.,
Office of Technology Transfer,
[[Page 4285]]
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, MD 20852-3804; E-mail: ThalhamC@mail.nih.gov; Telephone:
301-435-4507; Facsimile: 301-402-0220.
SUPPLEMENTARY INFORMATION: The prospective co-exclusive license will be
royalty bearing and will comply with the terms and conditions of 35
U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be
granted unless, within 60 days from the date of this published Notice,
NIH receives written evidence and argument that establishes that the
grant of the license would not be consistent with the requirements of
35 U.S.C. 209 and 37 CFR 404.7.
The technology described and claimed in the subject invention
relates to methods to enhance and prolong the body's immune response as
well as to promote targeted tissue damage, such as for tumor
destruction, by inhibiting signaling through the adenosine receptor.
The inventors have shown that adenosine A2a and A3a receptors play a
critical and non-redundant role in down-regulation of inflammation in
vivo by acting as the physiological termination mechanism that can
limit the immune response. The methods described involve administering
either an adenosine-degrading drug or an adenosine receptor antagonist
to exert a more effective and durable immune response and inflammation,
and more specifically to the subject exclusive license application, to
reduce the size of tumors. Furthermore, using the claimed method in
combination with conventional anti tumor agent can be an effective
treatment against cancer.
The invention has potential applications in the many markets in
which therapeutic and preventive uses of manipulating the adenosine
pathway are involved, including the regulation of hypoxia, tissue
damage, tumor destruction, inflammation, increasing the efficacy of
vaccines, and other immune responses.
This invention is further described in Ohta A et al., ``Role of G-
protein-coupled adenosine receptors in down-regulation of inflammation
and protection from tissue damage,'' Nature 2001 Dec 20-27;
414(6866):916-20.
The field of use may be limited to ``Prevention and treatment of
human cancer and tumors by inhibitors of any or all of the adenosine
receptor subtypes covered by the Licensed Patent Rights''.
Properly filed competing applications for a license filed in
response to this notice will be treated as objections to the
contemplated license. Comments and objections submitted in response to
this notice will not be made available for public inspection, and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
This announcement is a supplement to the one published in the
Federal Register on April 11, 2005 (70 FR 18419).
Dated: January 18, 2007.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E7-1376 Filed 1-29-07; 8:45 am]
BILLING CODE 4140-01-P